EGFR and lung carcinoma: The FDA has approved the use of two EGFR-targeted molecules, gefitinib ("Iressa" from Astra Zeneca) and erlotinib ("Tarceva" from Genentech/Roche) in the second- and third-line treatment of lung cancer.